Hangzhou Tigermed Consulting Co., a Chinese clinical research service provider, has picked banks to arrange a Hong Kong share sale that could raise at least $500 million, people familiar with the matter said.
The Shenzhen-listed company has selected Bank of America Corp. and CLSA Ltd. to work on the stock offering, the people said, asking not to be identified because the matter is private. The Hong Kong listing could take place as soon as the second half of next year, according to the people.
